Formulation Development
Micron Biomedical Extends Series A Financing to 33+ Million to Accelerate Commercialization of Needle-Free Therapeutics & Vaccines
Micron Biomedical, a life science company developing the world’s first needle-free technology for drugs and vaccines that is based on dissolvable microarrays, today announced it…
ReciBioPharm Secures Significant Grant to Advance RNA Manufacturing
ReciBioPharm, a division of Recipharm and a leading Contract Development and Manufacturing Organization (CDMO), has been awarded a 3-year grant from the Bill & Melinda…
Palisade Bio Completes All Five SAD Cohorts & Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis
Palisade Bio, Inc recently announced the completion of all five planned Single Ascending Dose (SAD) cohorts and the commencement of the Multiple Ascending Dose (MAD)…
Nipro & Nemera Prove Compatibility of Unit-Dose Microvials & UniSpray
Nipro PharmaPackaging and Nemera recently announced the successful compatibility testing of Nemera’s UniSpray and Nipro’s unit-dos microvials. This collaboration aims to accelerate the time to…
Lyndra Therapeutics Announces Strategic Clinical Research & Commercial Manufacturing Services Collaboration With Thermo Fisher Scientific
Lyndra Therapeutics recently announced a strategic collaboration with Thermo Fisher Scientific Inc., the world leader in serving science, in which Thermo Fisher will provide global…
Attralus Announces Enrollment of First Patient in Phase 3 Trial for the Pan-Amyloid Diagnostic 124I-evuzamitide (AT-01) for Cardiac Amyloidosis
Attralus, Inc. recently announced the enrollment of the first patient in the Research with 124I-EVuzamitide to Elucidate Cardiac AmyLoidosis (REVEAL) study – A Phase 3…
Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase 2b/3 Data
Anavex Life Sciences Corp. recently announced the The Journal of Prevention of Alzheimer’s Disease (JPAD) has published peer-reviewed detailed results from the Phase 2b/3 study…
Abzena Strengthens Board With Appointment of Biopharma Industry Leader, Dr. Moncef Slaoui
Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has today announced the appointment of Moncef Slaoui, PhD, to its Board…
Iconovo & Lonza to Collaborate on the Formulation Development of an Intranasal Biologic
Iconovo AB, a leader in the development of inhalable drugs based on proprietary inhalers and dry powder formulations, today announced that Iconovo and Lonza initiated…
Alcami Announces CEO Transition
[caption id="attachment_144551" align="alignleft" width="153"] Patrick Walsh[/caption] Alcami Corporation, a leading contract development and manufacturing organization (CDMO), recently announced the resignation of Bill Humphries. Alcami’s Board…
BioMed X Institute Launches New Collaboration With Daiichi Sankyo in Cancer Therapy
BioMed X recently announced the launch of a new collaboration with Daiichi Sankyo Co., Ltd., a global pharmaceutical company headquartered in Japan. This collaboration marks the…
PulseSight Therapeutics Announces Initiation of Clinical Plan of Transferrin Vectorized Therapy for Dry AMD/Geographic Atrophy
PulseSight Therapeutics SAS recently announced it has submitted a Clinical Trial Authorization (CTA) to Agence Nationale de Sécurité du Médicament et des produits de santé…
Pheno Therapeutics Granted Clinical Trial Authorization for Lead Multiple Sclerosis Therapeutic Candidate
Pheno Therapeutics Limited recently announced it has received clinical trial authorization (CTA) from the UK’s MHRA (Medicines and Healthcare products Regulatory Agency) for its lead…
Sling Therapeutics Announces Positive Topline Results From Phase 2b/3 Trial of Oral Small Molecule Linsitinib in Patients With Thyroid Eye Disease
Sling Therapeutics, Inc. recently announced topline efficacy and safety data from the Phase 2b/3 LIDS trial of linsitinib in patients with active, moderate to severe…
Invivyd Announces Continued Neutralizing Activity of PEMGARDA Against Dominant SARS-CoV-2 Variant XEC
Invivyd, Inc. recently announced new in vitro neutralization data show continued neutralizing activity of PEMGARDA (pemivibart) and pipeline candidate VYD2311 against dominant SARS-CoV-2 variant XEC.…
BioDuro Opens New Solid-Phase Peptide Synthesis Scale-Up Facility
BioDuro, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), recently announced the opening of a fully-automated solid-phase peptide synthesis scale-up laboratory at its Shanghai…
Windward Bio Launches With $200-Million Financing to Develop Phase 2-Ready, Long-Acting Anti-TSLP Antibody With Best-in-Class Potential in Asthma & COPD
Windward Bio recently announced its official launch. OrbiMed, Novo Holdings, and Blue Owl Healthcare Opportunities lead the Series A financing of $200M with the co-investment…
Menarini Group & Insilico Medicine Enter Second Exclusive Global License Agreement
The Menarini Group, Stemline Therapeutics, Inc., and Insilico Medicine recently announced the companies have entered into an exclusive licensing agreement granting Stemline the global rights…
Genenta Strengthens Agreement With AGC Biologics to Boost Cell Therapy Manufacturing
Genenta Science recently announced it has strengthened its partnership with AGC Biologics, a global contract development and manufacturing organization (CDMO), by amending their Development and…
Boehringer Ingelheim Acquires Fourth License for the Development of Novel Antibody-Based Cancer Treatments From Oxford BioTherapeutics
Oxford BioTherapeutics (OBT) recently announced Boehringer Ingelheim has exercised an option for rights to a fourth novel oncology target from an ongoing discovery collaboration. The…
